(Q39964308)

15 September 2017

title

Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection (English)

1 reference

15 September 2017

0 references

0 references

Joachim Brouwers

1

0 references

Kurt Vermeire

object named as

Kurt Vermeire

series ordinal

2

0 references

Patrick F Augustijns

object named as

Patrick Augustijns

series ordinal

4

0 references

Dominique Schols

object named as

Dominique Schols

series ordinal

3

0 references

language of work or name

English

0 references

publication date

7 July 2008

1 reference

15 September 2017

1 reference

15 September 2017

volume

378

1 reference

15 September 2017

issue

2

1 reference

15 September 2017

page(s)

306-310

1 reference

Microbicide drug candidates to prevent HIV infection

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

The additive in vitro anti-HIV-1 effect of chloroquine, when combined with zidovudine and hydroxyurea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Development pharmaceutics of microbicide formulations. Part II: formulation, evaluation, and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Comparison of the mucoadhesive properties of various polymers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Interpreting properties of microbicide drug delivery gels: analyzing deployment kinetics due to squeezing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Which topical microbicides for blocking HIV-1 transmission will work in the real world?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

7 January 2021

A vaginal fluid simulant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Rheological properties of contraceptive gels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

A review of the physical and chemical properties of human semen and the formulation of a semen simulant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Biophysical analysis of prototype microbicidal gels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

HIV/AIDS in women: an expanding epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Immunomodulatory role of chloroquine and pyrimethamine in Plasmodium yoelii 17XL infected mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

The anti-HIV-1 activity of chloroquine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Effects of chloroquine on viral infections: an old drug against today's diseases?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

New insights into the antiviral effects of chloroquine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Chloroquine-resistant malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.06.005

Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy.

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18606432

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2008.06.005

1 reference

15 September 2017

1 reference